FDA sets dissolution, weight standards for orally disintegrating tablets
FDA has issued a final guidance that recommends limiting orally disintegrating tablets to a 30-second dissolution time and a weight of no more than 500 mg. FDA stated, however, that it was willing to be flexible on the weight requirement. If the ODT weighs more than 500 mg., sponsors must demonstrate that "its ability to perform effectively as an ODT should be justified based on product performance." The agency, however, refused to budge on the time limit requirement. Industry objected to the 30-second time limit when it was proposed in the 2007 draft guidance, recommending instead a 60-second limit, but to no avail. The guidance notes that "tablets that take longer than 30 seconds to disintegrate or are dosed with liquids may be more appropriately considered to be chewable or oral tablets." The guidance provides pharmaceutical manufacturers of new and generic drug products with an agency perspective on the definition of an orally disintegrating tablet (ODT), which is a different dosage form than, for example, a chewable tablet or a tablet that should be swallowed whole with liquid
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.
HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.
Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.